GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » FCF Yield %

Theriva Biologics (Theriva Biologics) FCF Yield % : -266.86 (As of Apr. 27, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Theriva Biologics's Trailing 12-Month Free Cash Flow is $-19.20 Mil, and Market Cap is $7.19 Mil. Therefore, Theriva Biologics's FCF Yield % for today is -266.86%.

The historical rank and industry rank for Theriva Biologics's FCF Yield % or its related term are showing as below:

TOVX' s FCF Yield % Range Over the Past 10 Years
Min: -365.51   Med: 0   Max: 0
Current: -266.86


TOVX's FCF Yield % is ranked worse than
93.61% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs TOVX: -266.86

Theriva Biologics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.


Theriva Biologics FCF Yield % Historical Data

The historical data trend for Theriva Biologics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics FCF Yield % Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -162.84 -108.70 -35.90 -279.10 -260.30

Theriva Biologics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -312.16 -212.75 -91.56 -134.13 -357.78

Competitive Comparison of Theriva Biologics's FCF Yield %

For the Biotechnology subindustry, Theriva Biologics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's FCF Yield % falls into.



Theriva Biologics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Theriva Biologics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-19.198 / 7.37539781
=-260.30%

Theriva Biologics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-6.597 * 4 / 7.37539781
=-357.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theriva Biologics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Theriva Biologics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (Theriva Biologics) Business Description

Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics (Theriva Biologics) Headlines

From GuruFocus

Could Insider Buying Signal that Theriva Biologics Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 01-23-2023